X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-18 | PSNL | Personalis, Inc. | Tachibana Aaron | CFO, COO | S - Sale | $3.79 | -1,307 | 173,963 | -1% | -$4,954 | ||||||
2024-11-18 | PSNL | Personalis, Inc. | Moore Stephen Michael | SVP, GC | S - Sale | $3.79 | -1,693 | 67,388 | -2% | -$6,416 | ||||||
2024-11-18 | PSNL | Personalis, Inc. | Chen Richard | Chief Medical Officer, EVP | S - Sale | $3.79 | -921 | 128,720 | -1% | -$3,491 | ||||||
2024-11-15 | XGN | Exagen Inc. | Black Jeffrey G. | CFO | P - Purchase | $2.98 | +22,298 | 274,492 | +9% | +$66,448 | ||||||
2024-11-18 | GH | Guardant Health, Inc. | Kalia Kumud | CIO | S - Sale | $29.25 | -7,000 | 17,744 | -28% | -$204,722 | ||||||
2024-11-18 | GRAL | Grail, Inc. | Freidin Aaron | CFO | S - Sale | $14.02 | -30,452 | 268,277 | -10% | -$426,937 | ||||||
2024-11-15 | CSTL | Castle Biosciences Inc | Stokes Frank | CFO | S - Sale | $29.93 | -6,923 | 30,823 | -18% | -$207,217 | ||||||
2024-11-14 | XGN | Exagen Inc. | Aballi John | Pres, CEO | P - Purchase | $2.81 | +24,305 | 689,799 | +4% | +$68,297 | ||||||
| D | 2024-11-15 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $146.11 | -37,230 | 15,807 | -70% | -$5,439,565 | |||||
2024-11-15 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $146.41 | -4,728 | 371,911 | -1% | -$692,209 | ||||||
2024-11-13 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $154.86 | -36,300 | 355,336 | -9% | -$5,621,396 | ||||||
2024-11-14 | NTRA | Natera, Inc. | Marcus Gail Boxer | Dir | S - Sale | $158.53 | -2,212 | 19,386 | -10% | -$350,672 | ||||||
2024-11-12 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $34.15 | -5,127 | 399,840 | -1% | -$175,087 | ||||||
2024-11-13 | GH | Guardant Health, Inc. | Joyce Meghan V. | Dir | S - Sale | $29.90 | -2,896 | 7,648 | -27% | -$86,595 | ||||||
| D | 2024-11-12 | GH | Guardant Health, Inc. | Clark Ian T | Dir | S - Sale+OE | $29.45 | -8,318 | 8,435 | -50% | -$244,930 | |||||
2024-11-12 | VCYT | Veracyte, Inc. | Chambers Rebecca | CFO | S - Sale | $38.34 | -15,275 | 124,501 | -11% | -$585,663 | ||||||
| D | 2024-11-12 | VCYT | Veracyte, Inc. | Epstein Robert S | Dir | S - Sale+OE | $38.32 | -15,000 | 44,598 | -25% | -$574,830 | |||||
| DM | 2024-11-11 | BDSX | Biodesix Inc | Vazquez Chris | Chief Accounting Officer | S - Sale+OE | $1.40 | -203 | 11,587 | -2% | -$283 | |||||
| DM | 2024-11-11 | BDSX | Biodesix Inc | Pestano Gary Anthony | Chief Development Officer | S - Sale+OE | $1.40 | -427 | 127,027 | 0% | -$596 | |||||
| DM | 2024-11-11 | BDSX | Biodesix Inc | O'Kane Kieran | Chief Commercial Officer | S - Sale+OE | $1.40 | -462 | 97,448 | 0% | -$645 | |||||
| DM | 2024-11-11 | BDSX | Biodesix Inc | Hutton Scott | Pres, CEO | S - Sale+OE | $1.40 | -3,740 | 532,979 | -1% | -$5,220 | |||||
| DM | 2024-11-11 | BDSX | Biodesix Inc | Cowie Robin Harper | CFO, Sec'y, Treasurer | S - Sale+OE | $1.40 | -971 | 203,336 | 0% | -$1,355 | |||||
2024-11-13 | EXAS | Exact Sciences Corp | Conroy Kevin T | Pres, CEO | P - Purchase | $51.35 | +19,500 | 1,414,311 | +1% | +$1,001,325 | ||||||
2024-11-11 | LH | Labcorp Holdings Inc. | Schechter Adam H | Pres, CEO | S - Sale | $243.47 | -6,189 | 87,441 | -7% | -$1,506,836 | ||||||
2024-11-08 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $130.78 | -5,700 | 391,636 | -1% | -$745,471 | ||||||
2024-11-11 | SERA | Sera Prognostics, Inc. | Mirza Mansoor Raza | Dir | S - Sale | $7.32 | -95 | 6,729 | -1% | -$695 | ||||||
2024-11-11 | SERA | Sera Prognostics, Inc. | Lindgardt Zhenya | CEO | S - Sale | $7.32 | -12,075 | 819,758 | -1% | -$88,389 | ||||||
2024-11-11 | SERA | Sera Prognostics, Inc. | Kearney Paul | Chief Data Officer | S - Sale | $7.32 | -4,078 | 176,889 | -2% | -$29,851 | ||||||
2024-11-11 | SERA | Sera Prognostics, Inc. | Jackson Benjamin | GC | S - Sale | $7.32 | -4,727 | 135,528 | -3% | -$34,602 | ||||||
2024-11-11 | SERA | Sera Prognostics, Inc. | Harrison Robert Gardner | CIO | S - Sale | $7.32 | -4,727 | 131,046 | -3% | -$34,602 | ||||||
2024-11-11 | SERA | Sera Prognostics, Inc. | Boniface John J. | Chief Scientific Officer | S - Sale | $7.32 | -4,727 | 125,120 | -4% | -$34,602 | ||||||
2024-11-11 | SERA | Sera Prognostics, Inc. | Aerts Austin | CFO | S - Sale | $7.32 | -7,179 | 291,486 | -2% | -$52,550 | ||||||
| D | 2024-11-06 | DGX | Quest Diagnostics Inc | Deppe Michael J | SVP, Corp. Controller, CAO | S - Sale+OE | $154.05 | -18,755 | 35,632 | -34% | -$2,889,123 | |||||
| D | 2024-11-05 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale+OE | $35.56 | -3,507 | 56,408 | -6% | -$124,709 | |||||
2024-11-04 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $32.54 | -5,127 | 404,967 | -1% | -$166,820 | ||||||
2024-11-05 | BDSX | Biodesix Inc | Strobeck Matthew | Dir | P - Purchase | $1.40 | +40,000 | 5,756,157 | +1% | +$55,916 | ||||||
2024-11-05 | BDSX | Biodesix Inc | Schuler Jack W | Dir, 10% | P - Purchase | $1.36 | +100,253 | 30,894,935 | 0% | +$136,585 | ||||||
2024-11-05 | BDSX | Biodesix Inc | Patience John | Chairman | P - Purchase | $1.38 | +75,000 | 7,373,823 | +1% | +$103,710 | ||||||
2024-11-05 | BDSX | Biodesix Inc | Massarany Hany | Dir | P - Purchase | $1.37 | +22,500 | 337,131 | +7% | +$30,866 | ||||||
| M | 2024-11-05 | BDSX | Biodesix Inc | Kennedy Lawrence T. Jr | Dir, 10% | P - Purchase | $1.36 | +71,200 | 25,419,283 | 0% | +$97,068 | |||||
| D | 2024-11-01 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale+OE | $35.39 | -3,100 | 56,408 | -5% | -$109,709 | |||||
2024-11-01 | CSTL | Castle Biosciences Inc | Bradbury Daniel | Dir | S - Sale | $34.73 | -7,867 | 36,892 | -18% | -$273,251 | ||||||
2024-11-01 | PSNL | Personalis, Inc. | Hall Christopher M | Pres, CEO | S - Sale | $5.38 | -26,443 | 178,098 | -13% | -$142,263 | ||||||
2024-10-31 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $126.45 | -1,866 | 68,851 | -3% | -$235,956 | ||||||
2024-10-28 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $118.21 | -1,057 | 206,027 | -1% | -$124,948 | ||||||
2024-10-28 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $118.21 | -1,196 | 110,695 | -1% | -$141,380 | ||||||
2024-10-28 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $118.21 | -929 | 113,136 | -1% | -$109,818 | ||||||
2024-10-28 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $118.21 | -3,960 | 189,762 | -2% | -$468,114 | ||||||
| M | 2024-10-28 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $118.86 | -1,992 | 70,717 | -3% | -$236,772 | |||||
2024-10-28 | DGX | Quest Diagnostics Inc | Kuppusamy Karthik | SVP, Clinical Solutions | S - Sale | $156.92 | -1,775 | 11,656 | -13% | -$278,525 | ||||||
| M | 2024-10-24 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $119.03 | -1,605 | 72,709 | -2% | -$191,037 | |||||
| D | 2024-10-23 | CELC | Celcuity Inc. | Buller Richard E | Dir | S - Sale+OE | $16.25 | -350 | 7,760 | -4% | -$5,688 | |||||
2024-10-24 | LH | Labcorp Holdings Inc. | Anderson Kerrii B | Dir | S - Sale | $230.00 | -1,000 | 14,010 | -7% | -$230,000 | ||||||
| M | 2024-10-21 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $120.44 | -550 | 111,891 | 0% | -$66,241 | |||||
| M | 2024-10-21 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $120.50 | -541 | 114,065 | 0% | -$65,193 | |||||
| D | 2024-10-23 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale+OE | $119.09 | -496 | 74,314 | -1% | -$59,068 | |||||
| DM | 2024-10-21 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale+OE | $120.46 | -816 | 207,084 | 0% | -$98,298 | |||||
| DM | 2024-10-21 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale+OE | $120.52 | -2,602 | 193,722 | -1% | -$313,597 | |||||
| DM | 2024-10-21 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale+OE | $120.46 | -1,062 | 73,560 | -1% | -$127,932 | |||||
2024-10-15 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $130.40 | -4,523 | 191,163 | -2% | -$589,797 | ||||||
2024-10-15 | GRAL | Grail, Inc. | Ragusa Robert P | CEO | S - Sale | $14.02 | -123,454 | 612,661 | -17% | -$1,730,825 | ||||||
2024-10-14 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $32.27 | -5,127 | 410,094 | -1% | -$165,464 | ||||||
| M | 2024-10-01 | GRAL | Grail, Inc. | Ding Chun R | 10% | P - Purchase | $13.00 | +78,829 | 3,644,855 | +2% | +$1,024,698 | |||||
2024-10-08 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $30.27 | -2,562 | 415,221 | -1% | -$77,549 | ||||||
2024-10-08 | EXAS | Exact Sciences Corp | Baranick Brian | EVP, GM, Precision Oncology | S - Sale | $70.00 | -929 | 13,212 | -7% | -$65,030 | ||||||
2024-10-07 | CSTL | Castle Biosciences Inc | Bradbury Daniel | Dir | S - Sale | $29.44 | -7,867 | 44,759 | -15% | -$231,628 | ||||||
| DEM | 2024-08-05 | OPGN | Opgen Inc | Aei Capital Ltd | 10% | S - Sale+OE | $0.57 | -2,400,000 | 7,645,603 | -24% | -$1,367,347 | |||||
| DEM | 2024-08-13 | OPGN | Opgen Inc | Aei Capital Ltd | 10% | P - Purchase | $0.98 | +5,245,603 | 7,645,603 | +219% | +$5,153,211 | |||||
2024-10-04 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $28.73 | -2,565 | 417,783 | -1% | -$73,703 | ||||||
2024-10-07 | SERA | Sera Prognostics, Inc. | Mirza Mansoor Raza | Dir | S - Sale | $7.15 | -96 | 6,824 | -1% | -$686 | ||||||
2024-10-01 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $125.64 | -5,700 | 396,905 | -1% | -$716,137 | ||||||
2024-09-27 | VRDN | Viridian Therapeutics, Inc.de | Beetham Thomas W. | COO | P - Purchase | $23.41 | +5,000 | 6,000 | +500% | +$117,050 | ||||||
2024-09-27 | VRDN | Viridian Therapeutics, Inc.de | Mahoney Stephen F. | Pres, CEO | P - Purchase | $23.33 | +21,400 | 21,400 | New | +$499,262 | ||||||
2024-09-19 | VCYT | Veracyte, Inc. | Jones Evan/ Fa | Dir | S - Sale | $35.23 | -5,173 | 34,343 | -13% | -$182,263 | ||||||
2024-09-18 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $127.60 | -22,000 | 402,605 | -5% | -$2,807,237 | ||||||
2024-09-18 | EXAS | Exact Sciences Corp | Baranick Brian | EVP, GM, Precision Oncology | S - Sale | $70.00 | -929 | 14,141 | -6% | -$65,030 | ||||||
2024-09-16 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $128.48 | -5,024 | 195,686 | -3% | -$645,474 | ||||||
2024-09-16 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $30.97 | -5,127 | 420,348 | -1% | -$158,793 | ||||||
2024-09-13 | VRDN | Viridian Therapeutics, Inc.de | Fairmount Funds Management LLC | Dir, 10% | P - Purchase | $18.75 | +1,600,000 | 3,445,813 | +87% | +$30,000,000 | ||||||
| D | 2024-09-13 | NTRA | Natera, Inc. | Chapman Rowan E | Dir | S - Sale+OE | $127.68 | -2,614 | 7,969 | -25% | -$333,756 | |||||
2024-09-11 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $30.32 | -2,616 | 425,475 | -1% | -$79,317 | ||||||
2024-09-09 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $29.46 | -2,586 | 428,091 | -1% | -$76,176 | ||||||
2024-09-10 | SERA | Sera Prognostics, Inc. | Aerts Austin | CFO | S - Sale | $7.57 | -5,056 | 298,665 | -2% | -$38,274 | ||||||
2024-09-10 | SERA | Sera Prognostics, Inc. | Lindgardt Zhenya | CEO | S - Sale | $7.57 | -25,085 | 831,833 | -3% | -$189,893 | ||||||
2024-09-06 | SERA | Sera Prognostics, Inc. | Mirza Mansoor Raza | Dir | S - Sale | $7.16 | -96 | 6,920 | -1% | -$687 | ||||||
2024-09-05 | CSTL | Castle Biosciences Inc | Bradbury Daniel | Dir | S - Sale | $29.02 | -7,867 | 52,626 | -13% | -$228,332 | ||||||
2024-09-04 | VCYT | Veracyte, Inc. | Leite John | Chief Commercial Officer-CLIA | S - Sale | $29.78 | -5,479 | 76,174 | -7% | -$163,159 | ||||||
2024-09-03 | FLGT | Fulgent Genetics, Inc. | Kim Paul | CFO, Treasurer | S - Sale | $21.96 | -1,674 | 209,481 | -1% | -$36,763 | ||||||
2024-09-03 | FLGT | Fulgent Genetics, Inc. | Xie Jian | Pres, COO | S - Sale | $21.96 | -1,594 | 561,986 | 0% | -$35,006 | ||||||
2024-09-03 | FLGT | Fulgent Genetics, Inc. | Gao Hanlin | Chief Scientific Officer | S - Sale | $21.96 | -1,503 | 923,057 | 0% | -$33,007 | ||||||
| M | 2024-09-03 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $30.04 | -1,914 | 430,677 | 0% | -$57,493 | |||||
2024-09-03 | CSTL | Castle Biosciences Inc | Oelschlager Kristen M | COO | S - Sale | $29.21 | -5,832 | 134,841 | -4% | -$170,330 | ||||||
| D | 2024-08-29 | DGX | Quest Diagnostics Inc | Prevoznik Michael E | SVP, GC | S - Sale+OE | $154.97 | -32,551 | 44,070 | -42% | -$5,044,516 | |||||
| M | 2024-08-29 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $30.08 | -4,441 | 432,591 | -1% | -$133,584 | |||||
2024-08-27 | FLGT | Fulgent Genetics, Inc. | Gao Hanlin | Chief Scientific Officer | S - Sale | $22.83 | -563 | 924,560 | 0% | -$12,855 | ||||||
2024-08-27 | FLGT | Fulgent Genetics, Inc. | Xie Jian | Pres, COO | S - Sale | $22.83 | -715 | 563,580 | 0% | -$16,326 | ||||||
2024-08-27 | FLGT | Fulgent Genetics, Inc. | Hsieh Ming | CEO, 10% | S - Sale | $22.83 | -2,313 | 8,825,206 | 0% | -$52,813 | ||||||
2024-08-27 | FLGT | Fulgent Genetics, Inc. | Kim Paul | CFO, Treasurer | S - Sale | $22.83 | -733 | 211,155 | 0% | -$16,737 | ||||||
2024-08-28 | DGX | Quest Diagnostics Inc | Kuppusamy Karthik | SVP, Clinical Solutions | S - Sale | $153.26 | -1,990 | 13,373 | -13% | -$304,990 | ||||||
| D | 2024-08-23 | CELC | Celcuity Inc. | Buller Richard E | Dir | S - Sale+OE | $16.95 | -350 | 8,110 | -4% | -$5,933 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |